Celgene's Oral REVLIMID Plus Dexamethasone Given Approval to Treatment Patients with Newly Diagnosed Multiple Myeloma in Japan
December 21, 2015 at 04:23 AM EST
Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ: CELG) today announced that REVLIMID® ...